Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 5/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 3/20 | 0.41 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29589462 | 1.00 | CHRM5 (0.44) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL1051987 | 1.00 | CHRM5 (0.44) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL30824576 | 1.00 | CHRM5 (0.44) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL859148 | 1.00 | CHRM5 (0.44) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL29394965 | 1.00 | CHRM5 (0.44) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| Hydrochloric Acid SCHEMBL839730 | 0.98 | CHRM5 (0.43) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| Hydrochloric Acid SCHEMBL839085 | 0.98 | CHRM5 (0.43) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL1764675 | 0.94 | KDM4E (0.46) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL30008129 | 0.94 | KDM4E (0.46) | CHRM5CHRM3CHRM2CHRM1CHRM4 | |
| SCHEMBL30812563 | 0.94 | KDM4E (0.46) | CHRM5CHRM3CHRM2CHRM1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166646-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | NEWAVE PHARMACEUTICAL INC. | 2024-05-23 | — | — | US | disclosed |
| US-20230033360-A1 | COMPOUNDS AS CD73 INHIBITORS | BIOARDIS LLC | 2023-02-02 | — | — | US | disclosed |
| CN-115490708-A | Sulfonamide macrocyclic derivatives, and preparation method and application thereof | 苏州亚盛药业有限公司 | 2022-12-20 | — | — | CN | disclosed |
| CN-114945578-A | Compounds as CD73 inhibitors | 博奥阿迪斯生物科技公司 | 2022-08-26 | — | — | CN | disclosed |
| WO-2022140224-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | NEWAVE PHARMACEUTICAL INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20220204539-A1 | CD73 INHIBITORS | BIOARDIS LLC | 2022-06-30 | — | — | US | disclosed |
| CN-114478520-A | Bcl-2 protein apoptosis inducer and application thereof | 杭州和正医药有限公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2022089463-A1 | BCL-2 PROTEIN APOPTOSIS-INDUCING AGENT AND APPLICATION THEREOF | 杭州和正医药有限公司 | 2022-05-05 | — | — | WO | disclosed |
| CN-114286824-A | CD73 inhibitor | 博奥阿迪斯生物科技公司 | 2022-04-05 | — | — | CN | disclosed |
| EP-2331499-B1 | COLD MENTHOL RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-21 | — | — | EP | disclosed |
| EP-2331499-A1 | COLD MENTHOL RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010021878-A1 | COLD MENTHOL RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010021878-A1 | COLD MENTHOL RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | WO | disclosed |
| US-20100048589-A1 | Cold Menthol Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048589-A1 | Cold Menthol Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | US | disclosed |
| US-20100048589-A1 | Cold Menthol Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-25 | — | — | US | disclosed |
| EP-1165510-B1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2005-09-28 | — | — | EP | disclosed |
| EP-1165510-A1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-02 | — | — | EP | disclosed |
| US-6284785-B1 | HAVING ACTIVITY AS LIGANDS OF METABOTROPIC GLUTAMATE RECEPTORS | HOFFMANN- LA ROCHE INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2000058285-A1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166646-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | BCL2, BCL3, BCL2L1 | CHRM5 4783/4885CHRM3 4845/4885CHRM2 4666/4885 |
| US-20100048589-A1 | Cold Menthol Receptor Antagonists | TRPV1, TRPM2, TRPM6 | CHRM5 84/4885CHRM3 53/4885CHRM2 55/4885 |
| US-20230033360-A1 | COMPOUNDS AS CD73 INHIBITORS | ENTPD5, ENTPD1, NT5E | CHRM5 1652/4885CHRM3 1914/4885CHRM2 1836/4885 |
| US-20220204539-A1 | CD73 INHIBITORS | ENTPD5, ENTPD1, ENTPD2 | CHRM5 1209/4885CHRM3 1715/4885CHRM2 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.